JAK2 and acquired polycythemia vera: As presence of the JAK2 V617F allele is a risk factor for poor outcomes, including thrombosis [5, 6, 21], treatments that reduce the JAK2 V617F allele burden are anticipated to improve outcomes for patients with PV.